Intangia
Intangia is a London-based AI-native platform, founded 2022, that ingests biomedical evidence and applies burst detection algorithms to score emerging scientific opportunities for biopharma R&D, BD, and life sciences investor teams.
- Company typePrivate
- Founded2022
- HeadquartersLondon, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Intangia does
Intangia (legal entity Intangiable Ltd) is a London-based, privately held AI-native platform founded in 2022 that serves biopharma R&D, business development, and life sciences investor teams. The platform continuously ingests scientific literature, patents, clinical trials, company/deal activity, and investment data, then applies proprietary burst detection algorithms and translational pathway analysis to score emerging opportunities at the target, indication, and modality level before they reach consensus. Its outputs are structured as governance-ready decision artifacts—Momentum Intelligence, Prioritization Matrices, and Freedom-to-Operate analyses—designed for investment committees and R&D portfolio reviews rather than ad-hoc search or dashboarding.
The product is delivered as enterprise SaaS accessed via app.intangia.co through a demo-driven, quote-based sales motion with annual subscription contracts. An optional Private Data Integration module allows enterprise customers to overlay their internal proprietary data onto the public evidence layer through Snowflake, Databricks, or AWS connections, supporting enterprise-grade security and auditability requirements. Customers cited publicly include Sarepta Therapeutics (enterprise), Olgram Therapeutics (mid-market), and an unnamed mid-cap biotech, with named use cases spanning drug hunting, asset repurposing, indication expansion, portfolio prioritization, BD partner screening, and investor intelligence.
The company is venture-backed by F-Prime, participated in Snowflake's Winter 2026 Startup Accelerator cohort, and maintains content-distribution partnerships with BioDuro and Techspert. Revenue, funding totals, and pricing are not publicly disclosed, and the firm operates with a 1–10 employee headcount, placing it at an early commercial stage despite institutional investor endorsement.
Intangia firmographics
Firmographics- Name
- Intangia
- Legal name
- Intangiable Ltd
- Website
- https://intangia.co
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Intangia is a London-based AI-native platform, founded 2022, that ingests biomedical evidence and applies burst detection algorithms to score emerging scientific opportunities for biopharma R&D, BD, and life sciences investor teams.
- Ownership category
- akta.pro rank
Intangia industry classification
Industry- Product category
- Biopharma Intelligence Software
- NAICS
- Securities, Commodity Contracts, and Other Financial Investments and Related Activities (523)
- akta.pro industry
- AI/ML Platforms for Drug Discovery & Experiment OptimizationHealthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
Keywords
Where Intangia is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Intangia business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales
Revenue model
- Subscription SaaS Platform: SaaS platform providing decision support for R&D and portfolio strategy. The platform is accessed via app.intangia.co and involves a demo booking process, suggesting a subscription-based model with enterprise sales involvement.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise subscription pricing - terms not disclosed |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Intangia product offering
Product offeringCore offering
Intangia provides an AI-driven decision support platform for biopharma R&D and strategy teams. It ingests scientific, clinical, patent, company, deal, and investment data across the biopharma landscape and applies proprietary burst detection algorithms to detect and score emerging opportunities at the target, indication, and modality level. The output supports go/kill/resize decisions, portfolio prioritization, partner identification, and capital allocation through evidence-linked decision artifacts designed for governance and investment committee workflows.
Product overview
Intangia is a unified biopharma intelligence platform consisting of a core product (Intangia Platform) with integrated decision support capabilities. The platform combines evidence ingestion (literature, patents, trials, market signals), a translation engine for momentum detection, and decision artifacts (Momentum Intelligence, Prioritization Matrices, FTO Outputs) designed for governance and portfolio reviews. An optional Private Data Integration module enables enterprise customers to overlay internal data via Snowflake, Databricks, or AWS connections.
Differentiator
Problem solved
Functional benefit
Products and services
- Intangia Platform A SaaS decision support platform for biopharma R&D and strategy teams that ingests scientific, clinical, patent, company, deal, and investment data, applies proprietary burst detection algorithms and translational pathway analysis, and scores emerging opportunities at the target/indication/modality level to support go/kill/resize and portfolio allocation decisions.
Quantifiable outcome
- Identified 5 potential partners in weeks instead of the 5-6 months it would normally take
- +1 more outcomes
Companies that use Intangia
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
Intangia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability5 records
Feature8 records
Intangia partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor and core.
- BioDurominorIntangia collaborated with BioDuro on an article exploring how AI-driven target intelligence can support drug discovery teams. BioDuro's Integrated Discovery Platform (IDD) helps clients move from target to pre-clinical candidate. Olivier Collart, Founder of Intangia, was interviewed for the collaboration.
- TechspertminorTechspert and Intangia co-authored a report titled 'From White Space to Benchmark Space' analyzing HS therapy market intelligence. The report covers IRAK4, IL-1-axis therapies, and oral immunology assets. Techspert prepared the report powered by Intangia's platform.
- SnowflakecoreIntangia was selected for Snowflake's Winter 2026 Startup Accelerator cohort. The company is building its enterprise solutions on Snowflake's AI Data Cloud, enabling data engineering and customer intelligence capabilities. The accelerator accepted 49 startups and received over 500 applications.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
Intangia competitors and assessment
Company assessmentDirect peers
- Causaly: AI platform that builds a biomedical knowledge graph for scientists and strategists. Closely comparable to Intangia's AI-driven reasoning layer over scientific literature, patents, and clinical evidence for R&D decision support.
- AlphaSense: Enterprise intelligence platform combining proprietary content with AI search across filings, research, and expert calls. Comparable to Intangia in serving strategy and BD teams with AI-driven insight layers, with growing life-sciences coverage.
- BenchSci: AI platform for biomedical researchers that ingests papers and experimental data to surface reagents, methods, and targets. Comparable to Intangia in applying NLP/ML over scientific evidence for life-science R&D teams.
- DealForma: Biopharma deal and pipeline intelligence platform for business development and corporate strategy teams. Directly comparable to Intangia's BD-facing use case (partner screening, deal rationale, competitive landscape).
Broad incumbents
- Citeline (Norstella): Pharma intelligence suite covering clinical trials, drugs, deals, and pipeline analytics. Comparable to Intangia in serving biopharma BD and portfolio strategy, but as part of a much wider intelligence portfolio.
- Informa Pharma Intelligence: Long-established pharma intelligence provider (Trialtrove, Pharmaprojects, Citeline legacy, etc.). Competes with Intangia on deal/trial intelligence for biopharma BD teams at significantly greater scale.
- IQVIA: Largest global life-sciences data, analytics, and CRO player. Overlaps with Intangia across R&D decision support, pipeline intelligence, and portfolio strategy but offers a much broader portfolio of services and data products.
Emerging players
- Owkin: AI-for-biopharma company using federated learning across hospital data to accelerate drug discovery and development. Adjacent to Intangia's R&D decision support thesis with comparable buyer (biopharma R&D leaders) but different data layer.
- Insilico Medicine: AI-native drug discovery and development company using generative biology and target identification platforms. Comparable to Intangia in applying AI to identify and prioritize novel targets, though Insilico is asset-owner vs. software-vendor model.
- Komodo Health: Healthcare intelligence platform applying AI to patient-level claims and clinical data. Comparable to Intangia in offering an AI-driven decision support layer, but focused on real-world patient journeys rather than early scientific momentum.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Intangia compliance and trust
Trust signalCompliance1 record
Intangia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Intangia leadership team
Management profileNumber of profiles
Profiles1 record
Intangia funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Intangia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Intangia
What does Intangia do?
Intangia provides an AI-driven decision support platform for biopharma R&D and strategy teams. It ingests scientific, clinical, patent, company, deal, and investment data across the biopharma landscape and applies proprietary burst detection algorithms to detect and score emerging opportunities at the target, indication, and modality level. The output supports go/kill/resize decisions, portfolio prioritization, partner identification, and capital allocation through evidence-linked decision artifacts designed for governance and investment committee workflows.
Is Intangia a public or private company?
Intangia is a private company. It is classified as venture growth investor backed and is currently operating.
When was Intangia founded?
Intangia was founded in 2022. It employs 1 to 10 people.
Where is Intangia based?
Intangia is headquartered in London, United Kingdom, in the Europe region.
How does Intangia make money?
One revenue line is on record: subscription SaaS Platform.
Who are Intangia's main competitors?
Direct peers on record are Causaly, AlphaSense, BenchSci and DealForma. Broad incumbents are Citeline (Norstella), Informa Pharma Intelligence and IQVIA. Emerging players are Owkin, Insilico Medicine and Komodo Health.
Does Intangia have an API?
No public API is recorded for Intangia.
What industry is Intangia in?
Intangia's product category is Biopharma Intelligence Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 523.